About 20n
20n is a Healthcare company based in San Francisco (United States) founded in 2013. Computational tools are developed to engineer microbes for synthetic biology. It operates in the Healthcare and Technology sectors. 20n has raised $2.22 million across 2 funding rounds from investors including Khosla Ventures, Y Combinator and Blumberg Capital. Its focus areas include Life Sciences, Genomics, Applied Genomics and Synthetic Biology. Its competitors include Amyris, Pivot Bio and Ginkgo Bioworks; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2013 in San Francisco, United States, the company operates in the synthetic biology sector. Microbes such as E. coli and yeast are engineered with a mushroom-derived gene and over-expressed native genes PabABC and nhoA to convert sugar into acetaminophen. DNA blueprints depicting enzymatic pathways are provided. Data mining, machine learning, program synthesis, and natural language processing are combined to advance biotechnology applications.
- Total Equity Funding$2.22M (USD)
in 2 rounds
- Latest Funding Round$2.1M (USD), Seed
May 2015
- InvestorsKhosla Ventures
& 3 more
Funding Insights of 20n
20n has successfully raised a total of $2.22M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $2.1 million completed in May 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.22M
- Total Rounds 2
- Last Round Seed — $2.1M
- First Round $120,000
(Dec 2014)
- Investors Count 4
All 2 funding rounds of 20n with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2015 | $2.1M | Seed | – | – | |
| Dec 2014 | $120,000 | Seed | – | – |
4 investors in total: 4 institutional.
Investors in 20n
20n has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Khosla Ventures, Y Combinator and Blumberg Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage startups are accelerated via funding and educational programs. | ycombinator.com | Mountain View, United States | ||
Early-stage startups are funded by this venture capital firm. | 2004 | khoslaventures.com | Menlo Park, United States | |
Venture capital firm investing in early and growth stage technology companies. | blumbergcapital.com | |||
Tech focused early-stage micro VC firm investing in the US | greatoaksvc.com | New York, United States |
Investor details for 20n
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of 20n
3 dated milestones of 20n across 2 years, from founding to its latest funding, stage changes and deals.
- Founded 20n is founded.
- Funding First funding round of $120K.
- Funding Latest funding round, Seed, of $2.1M.
Competitors of 20n
20n has 3 listed competitors in our database, 3 of them funded. They include Amyris, Pivot Bio and Ginkgo Bioworks.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| amyris.com | 2003 | Emeryville, United States | $487.2M | 747 | Developer of renewable products for industrial solutions | |
| pivotbio.com | 2010 | Berkeley, United States | $618.08M | 256 | Nitrogen-fixing microbes for corn crop nutrition are developed and applied. | |
| ginkgobioworks.com | 2008 | Boston, United States | $795.75M | 1,218 | Gene editing-based cultured ingredients are provided for agriculture. |
Detailed competitors of 20n
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as 20n (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about 20n
20n was founded in 2013 and raised its 1st funding round 1 year after it was founded.
20n is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
20n is a funded company, having raised a total of $2.22M across 2 funding rounds to date. The company's 1st funding round was a Seed of $120K, raised on Dec 2014.
Founded in 2013 in San Francisco, United States, the company operates in the synthetic biology sector. Microbes such as E. coli and yeast are engineered with a mushroom-derived gene and over-expressed native genes PabABC and nhoA to convert sugar into acetaminophen. DNA blueprints depicting enzymatic pathways are provided. Data mining, machine learning, program synthesis, and natural language processing are combined to advance biotechnology applications.
20n's top competitors include Amyris, Ginkgo Bioworks and Pivot Bio.
20n has 4 investors. Key investors include Khosla Ventures, Y Combinator, Blumberg Capital, and Great Oaks Venture Capital.